Functional Medicine · Hormonal Health

The Journal

by Dr. Natasha Ryan, ND

Perimenopause · Mood & Cognition

It’s Not All in Your Head. It’s in Your Receptors.

A woman comes in at 46. No psychiatric history. Successful, functional, not a worrier. And for the past eighteen months she has been waking at three in the morning with her heart pounding for no reason she can identify, snapping at people she loves, and crying in her car before meetings.

She has been told she is stressed. She has been offered an antidepressant. Nobody has mentioned her hormones.

I want to be careful here, because there is a version of this conversation that becomes irresponsible — the version that tells women all mental health symptoms are hormonal and psychiatric care is unnecessary. That is wrong and it is dangerous. But the opposite error is just as common, and women are living inside it: treating a hormonally driven mood change as though it appeared from nowhere.

The receptor-level explanation

Start with progesterone, because it is the piece almost nobody explains.

Progesterone is metabolized into a compound called allopregnanolone. Allopregnanolone is a positive allosteric modulator at the GABA-A receptor — the same receptor system targeted by benzodiazepines. It is, functionally, one of your body’s own anti-anxiety compounds.

Progesterone is produced after ovulation. As ovulation becomes irregular in perimenopause — which begins years before your cycles look irregular — allopregnanolone production becomes irregular with it.

Sit with that. A calming input your nervous system has relied on monthly since adolescence starts arriving unpredictably. Not gone, which might be easier to adapt to. Unpredictable.

That is why perimenopausal anxiety so often has a specific quality women describe the same way: it comes in waves, it does not attach to anything, and it feels physical before it feels emotional. Heart first, thought second.

Your nervous system did not become fragile. One of its regulators started arriving on an unreliable schedule.

Estrogen, serotonin, and the depression window

Estrogen’s relationship with mood runs through different machinery. It influences serotonin synthesis, receptor density, and reuptake, along with dopamine and norepinephrine signaling. It also affects BDNF, involved in neuronal maintenance.

The epidemiology here is worth knowing, because it is stronger than most women realize: the menopausal transition is associated with elevated risk of depressive symptoms, including in women with no prior history. Researchers describe it as a window of vulnerability — comparable in structure to the postpartum period, which is another moment of rapid hormonal change with well-recognized psychiatric risk.

We take postpartum depression seriously. We screen for it. Somehow the same logic has not transferred to a transition that lasts years rather than months.

Women with a history of PMS, PMDD, or postpartum depression appear to be at higher risk during perimenopause — which makes mechanistic sense. Those conditions mark sensitivity to hormonal change rather than to any particular level. Perimenopause is change, sustained.

The cognitive piece, and the fear underneath it

Brain fog gets discussed as an inconvenience. In my experience it is the symptom that frightens women most, and they rarely say so out loud.

The word-finding pauses. Walking into a room with no idea why. Reading the same paragraph three times. More than one woman has told me, quietly, that she has wondered whether she is watching the beginning of dementia.

Here is what I tell them, and it is worth saying plainly: estrogen acts throughout the brain, including on neuronal glucose metabolism, and neuroimaging research has documented measurable changes in brain energy metabolism across the menopausal transition. The fog is a brain adapting to a changing hormonal environment. Studies following women through the transition generally find cognitive performance recovers as hormones stabilize afterward.

It is a feature of the transition. Not a trajectory.

That said — if cognitive symptoms are severe, progressive, or accompanied by other neurologic changes, that deserves proper evaluation rather than reassurance from a blog post.

What a real workup looks like

This is where functional medicine earns its keep, and it is less exotic than the phrase suggests. It is mostly refusing to accept a symptom as a diagnosis.

Before concluding that a woman in her forties has developed anxiety or depression, I want to know:

  • Full thyroid panel — not TSH alone. Free T3, free T4, reverse T3, and antibodies. Thyroid dysfunction produces anxiety, depression, and cognitive change almost indistinguishable from primary psychiatric illness, and it is dramatically more common in women in exactly this age band.
  • Ferritin, not just hemoglobin. Iron deficiency without anemia is common in still-cycling women, especially with the heavier periods of early perimenopause, and it produces fatigue, low mood, and poor concentration.
  • Vitamin D. Receptors sit in brain regions involved in mood regulation, and it participates in the steps that produce serotonin and dopamine. It is also required for calcium absorption, which matters for a woman losing bone — so it is worth knowing even setting mood aside. Most standard panels skip it unless someone asks.
  • B12. Required for the methylation that builds serotonin, dopamine, and norepinephrine. Deficiency produces depression, poor concentration, and memory complaints before anemia shows on a blood count, which is why checking a CBC and calling it done misses it. Metformin, acid-reducing medications, and plant-based eating all deplete it.
  • Fasting insulin and glucose. Blood sugar instability produces afternoon irritability and anxiety that gets read as psychological.
  • Sleep, including apnea screening. Sleep apnea is substantially underdiagnosed in women because it often presents as fatigue and insomnia rather than loud snoring. No mood intervention works well on top of it.
  • Hormonal status appropriate to her stage — interpreted against her cycle pattern, not from a single draw.
  • Medication review. A number of common medications affect mood.

I have watched a woman’s “anxiety” resolve on iron repletion. That is not a story about the power of supplements. It is a story about what happens when nobody checks.

What actually helps

Address the hormonal driver. If declining and erratic progesterone and estrogen are driving the picture, that is the conversation to have — with real information about hormone therapy rather than the residual fear from a twenty-year-old study most people have never read in full.

Protect sleep like it is treatment, because it is. Sleep deprivation independently produces anxiety and depressive symptoms. The perimenopausal 3 AM waking has its own physiology worth understanding — see why that hour specifically.

Strength training. Not for the body composition, though you get that too. The mood and cognitive evidence for resistance training in midlife women is genuinely good, and it is one of the few interventions that acts on bone, muscle, insulin sensitivity, and mood at once.

Protein and blood sugar stability. A woman running on coffee until two in the afternoon is riding a glucose curve all day, and the crashes at the bottom of it feel exactly like anxiety — shaky, irritable, suddenly tearful over nothing. Protein at breakfast flattens that curve. It is the least interesting recommendation I make and one of the ones women notice fastest.

And keep psychiatric care on the table. This is important. If a woman is significantly depressed, treating her hormones while she waits for a slow intervention to work is not a kindness. Antidepressants, therapy, and hormonal support are not competing options — they address different parts of the same picture, and the right answer is often more than one.

Please read this part: if you are having thoughts of harming yourself, this is not the moment for a root-cause workup. Reach out to a crisis line or your physician today. In the U.S. you can call or text 988. Depression during the menopausal transition is real and treatable, and getting immediate support does not mean giving up on finding the underlying cause — it means staying safe while you do.

What I want you to take from this

If you developed anxiety at 44 with no history of it, something changed. That something has a mechanism, and it is measurable.

You are allowed to ask for the full thyroid panel. You are allowed to ask about progesterone. You are allowed to say “I want to understand why this started” before you agree to manage it indefinitely.

Sometimes the answer is still that you need psychiatric care, and that is a legitimate and good answer. But it should be an answer arrived at, not assumed.

Frequently Asked Questions

Can perimenopause really cause anxiety with no prior history?

Yes. The allopregnanolone mechanism explains why — a GABA-modulating compound your nervous system relied on monthly starts arriving unpredictably. New-onset anxiety in the forties is common and has a physiological basis.

Should I take hormones instead of an antidepressant?

That is a decision for you and your physician, and it is not necessarily either-or. What matters is that the hormonal contribution gets evaluated rather than skipped.

Will the brain fog go away?

For most women, cognitive performance recovers as hormones stabilize after the transition. Severe or progressive symptoms warrant proper evaluation rather than waiting.

My doctor says my thyroid is fine — should I push?

Ask which markers were actually run. TSH alone is not a full thyroid evaluation, and “normal” on a lab report is a statistical range, not a statement about how you feel. See what standard panels leave out.

References

  1. Bromberger JT, et al. “Longitudinal change in reproductive hormones and depressive symptoms across the menopausal transition (SWAN).” Archives of General Psychiatry, 2010. View source
  2. “Correlation between allopregnanolone levels and depressive symptoms during late menopausal transition and early postmenopause.” PubMed, 2017. View source
  3. “Decreased GABA+ Levels in the Medial Prefrontal Cortex of Perimenopausal Women: A 3T 1H-MRS Study.” PubMed, 2022. View source
  4. Mosconi L, et al. “Increased Alzheimer’s risk during the menopause transition: A 3-year longitudinal brain imaging study.” PLOS ONE, 2018. View source

Where a compound is investigational, that is stated in the disclosure at the top of this article. Regulatory status was checked against FDA materials current at the time of publication.